TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety of aerobic training
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Total gastric content half emptying time T50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of Submental Skin Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Average BCVA Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Intravaginal Ejaculatory Latency Time (IELT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With >= 50% Reduction in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endometrium thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed ORR per blinded independent central review (BICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent Pigment Darkening (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Nausea and vertigo scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-6 and CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intraoperative driving pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraoperative transpulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraoperative respiratory system compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraoperative positive end-expiratory pressure (PEEP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of pro-angiogenic cytokines concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed 6 meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance on the agility t-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in chronic pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of differentially methylated CpG sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor-Functional Independence Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioural performance of health care teams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AFI-intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor-specific Anti-HLA Antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stand up - sit down five times test (FTSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Heart Rate From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Blood Pressure From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Good histological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma (AUC0-12h,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of the analyte in plasma (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing An Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinuing Study Treatment Due to An AE
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of β1 AAb negative participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of echocardiographic screening for CTEPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy Epworth Sleepiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in ascorbic acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline of PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Foot sole tactile threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Changes in level of cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in liver biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intraoperative and postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Whole body energy expenditure (WBEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of indacaterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in picture naming scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Free Elastase in Induced Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of oxidation, inflammation, and leucocyte activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline self-rated mental health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline self-rated measure of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Healthy unbroken skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: First Occurrence of a Severe Cardiovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with hemoglobin less than 10 g/dL
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in Respiratory Disturbance Index (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and toleration of lersivirine
Endpoint domain: Adverse events/effects
Primary endpoint: Effect of lersivirine on QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in WOMAC pain subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change from baseline in mean weekly VAS of leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative biliary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Excess limb volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumour cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FLR function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreasing pain after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant response rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective Response Rate (ORR) Unconfirmed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate (ORR) Confirmed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose (MTD) of MKC-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential detection ratio (DDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of patient comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of device-and procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with completed offline construction of pre- and post-treatment activation maps
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time taken to return to normal gait with comfort post surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borg Scale Rate of Perceived Exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maintenance of bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maintenance of lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance of muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maintenance of hand muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in plasma lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numerical Rated Pain Scale (NRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wheelchair Users Shoulder Pain Index (WUSPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on cortical excitability - motor evoked potential (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Days Children Are Out of School Sick
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pathomorphological changes of the pelvis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between D and A/F at the calf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vaginal Birth
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in faecal incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in AST at 14 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Participants with Adverse Events (Safety)
Endpoint domain: Adverse events/effects
Primary endpoint: To evaluate ALT normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: To evaluate AST normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Prothrombin Time (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in International Normalized Ratio (INR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Partial Thromboplastin Time (PTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Best Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of stenosis (50% occlusion) of major renal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient Pain Measured by Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in faecal sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-operative retinal micro-trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first recurrence of a suicide event
Endpoint domain: Mortality/survival
Primary endpoint: Number of suicide events after treatment
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the Time After Administration When the Maximum Plasma Concentration is Reached (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: composite of graft loss and death
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of predictive algorithm for acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of motexafin gadolinium (MGd) and rituximab added to high-dose chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity of MGd added to whole-brain radiotherapy (WBRT)
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor-selective uptake of MGd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Experienced At Least One Solicited Injection Site Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced At Least One Solicited Systemic Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced At Least One Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Pimecrolimus Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline fasting blood triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline fasting blood HDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline fasting blood sugar levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in forced exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Depressive symptoms change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological distress and well being change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cancer specific distress change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life using the Fact-G change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ratings of psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reactions during penicillin challenge tests
Endpoint domain: Adverse events/effects
Primary endpoint: Change in VO2 Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of QFR compared to iFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Knee Society Score (KSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Radiolucency/Bone Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Absence of Implant Revision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of Severe Knee-Related Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Lung Permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time of recurrence of an infection
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of procedure related and device related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant cerebrospinal fluid (CSF) pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of more than one grade in the Humphrey Field SITA Standard 24-2 Test grading scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference between measured and calculated serum osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in EPDS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in STAI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complication rate after TOETVA
Endpoint domain: Adverse events/effects
Primary endpoint: Return of Investment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of Medical Care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total alfentanil dose used during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The extent of respiratory depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Autoreactive T cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain as measured by the Visual Analog Scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of physical disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accessibility of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to ACS resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of major bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Mean abdominal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in prosodic skill assessment protocol subjective measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prosodic skill assessment protocol mean frequency measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Arabic prosodic assessment tool subjective ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac energy status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cellular respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with continued access to age appropriate formulation of dolutegravir
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of Class I lens event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in ALSFRS-Revised score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Neurological International Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: parent's satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Linkage to Care - CD4 T-cell Count Test Result Within 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timely Antiretroviral Therapy Initiation Within 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes